Shilan Ding1,2,3,4†Min Wang1,2,3,4†Song Fang5Huibo Xu6Huiting Fan7Yu Tian1,2,3,4Yadong Zhai1,2,3,4Shan Lu1,2,3,4Xin Qi7Fei Wei1,2,3,4Guibo Sun1,2,3,4*Xiaobo Sun1,2,3,4*1Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China2Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China3Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China4Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China5Kunming Shenghuo Pharmaceutical Group Co., Ltd., Kunming, China6Academy of Chinese Medical Sciences of Jilin Province, Jilin, China7Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

In the published article, there was an error in Figure 7 as published. In Figure 7, the Akt protein bands in the liver group and platelet group were the same in this study. The corrected Figure 7 and its caption, appear below.

Figure 7. Thrombopoietin-dependent signaling is enhanced with D-dencichine treatment in mouse liver, platelet, and spleen. (A–C) Western blots analysis of p-ERK1/2/ERK1/2, p-Akt/Akt proteins in liver, platelet, and spleen. Quantification analysis of TPO-dependent signaling proteins from the information in corresponding protein bands. (D) Effects of apoptosis-related protein expression with D-dencichine treatment in mouse platelet. The level of Bcl-2/Bax was determined by western blot. Quantification analysis of Bcl-2, Bax and Bcl-2/Bax expression ratio from the information in corresponding protein bands. ##P < 0.01 vs. control group; *P < 0.05, **P < 0.01 vs. model group.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: chemotherapy-induced thrombocytopenia, thrombopoietin, D-dencichine, platelets, cytokines, mouse

Citation: Ding S, Wang M, Fang S, Xu H, Fan H, Tian Y, Zhai Y, Lu S, Qi X, Wei F, Sun G and Sun X (2025) Corrigendum: D-dencichine regulates thrombopoiesis by promoting megakaryocyte adhesion, migration and proplatelet formation. Front. Pharmacol. 15:1504076. doi: 10.3389/fphar.2024.1504076

Received: 30 September 2024; Accepted: 23 December 2024;
Published: 23 January 2025.

Edited and reviewed by:

Jia-Bo Wang, Capital Medical University, China

Copyright © 2025 Ding, Wang, Fang, Xu, Fan, Tian, Zhai, Lu, Qi, Wei, Sun and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Guibo Sun, c3VuZ3VpYm9AMTI2LmNvbQ==; Xiaobo Sun, c3VuX3hpYW9ibzE2M0AxNjMuY29t

†Both authors contributed equally to this study and were considered as co-first authors